Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 237 publications.

Davis A, Cook C, Graham J, Diaz-Decaro J, Myers E, Buck P. Modelling the public health impact of routine pediatric vaccination for the prevention of cytomegalovirus and congenital cytomegalovirus at the population-level. Poster presented at the 41st Annual Meeting of ESPID 2023; May 8, 2023. Lisbon, Portugal.

Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States. Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x

Shamarina D, Sluga-O'Callaghan M, Dave V, Davenport E, Curran D, Deeywadaa P, Marijam A, Andani A. Knowledge and attitudes of European HCPs towards hepatitis A and B vaccination of adults at risk. Poster presented at the Global Hepatitis Summit 2023; April 25, 2023. Paris, France. Previously presented at the 15th European Public Health Conference 2022 (EPH).

George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2023 Canadian Immunization Conference; April 25, 2023. Ottawa, Canada. Previously presented at the 2022 Canadian Association for Population Therapeutics Conference.

Morrison LTR, Anderson B, Brower A, Talbird SE, Buell N, MacDonald PDM, Metz L, Gaudig M, Oriol Mathieu V, Honeycutt AA. Macroeconomic impact of Ebola outbreaks in Sub-Saharan Africa and potential mitigation of GDP loss with prophylactic Ebola vaccination programs. PLoS One. 2023 Apr 11;18(4):e0283721. doi: 10.1371/journal.pone.0283721

Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12(3):933-50. doi: 10.1007/s40121-023-00767-4

DeMuro C, Finelli L, Lewis S, Williams V, Martin E, Phillips M, Saretsky T, Osborne R, Norquist J. Assessing the patient experience of respiratory syncytial virus infection: development of a patient-reported outcome measure. Health Qual Life Outcomes. 2023 Feb 28;21(1):20. doi: 10.1186/s12955-022-02066-x

Molnar D, La E, Verelst F, Curran D, Poston S, Graham J. Modeling the clinical and economic burden of respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Talbird S, Cook C, DeMartino J, Hernandez-Pastor L, Krishnarajah G. Projected impact of RSV vaccine in US adults ≥ 60 years of age. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Masaquel C, Schley K, Wright K, Mauskopf J, Parrish RA, Presa JV, Hewlett, Jr. D. The impact of social determinants of health on meningococcal vaccination awareness, delivery, and coverage in adolescents and young adults in the United States: a systematic review. Vaccines (Basel). 2023 Jan 24;11(2):256. doi: 10.3390/vaccines11020256

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036

Mellott C, Jaworski R, Carrico J, Clinkscales M, Talbird S, Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568

Lopez A, del Amo M, Perdizet J, McDade C, Wilson M. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine pediatric national immunization program in Spain. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S99. doi: 10.1016/j.jval.2022.09.482

Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649

Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782

Salem A, Curran D, Carrico J, La EM, Lorenc S, Hicks K, Poston S, Carpenter CF. Public health impact and cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S159. doi: 10.1016/j.jval.2022.09.767

Herrera-Restrepo O, Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Buck PM. Hepatitis A and Hepatitis B vaccination in adult patients at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180

Herrera-Restrepo O, Davis K, Sweeney C, Davenport E, Ghaswalla P, Buck PO. Hepatitis A and B vaccination in adults at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180

Shamarina D, Sluga-O'Callaghan M, Dave V, Davenport E, Curran D, Marijam A, Andani A. Knowledge and attitudes of European HCPs towards hepatitis A and B vaccination of adults at risk. Poster presented at the 15th European Public Health Conference 2022 (EPH); November 9, 2022. Berlin, Germany.

George S, Carrico J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged 50 years and older. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.

George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.

Poulos C, Boeri M, Coulter JR, Huang L, Schley K, Pugh SJ. Travelers' preferences for tick-borne encephalitis vaccination. Expert Rev Vaccines. 2022 Oct 1;21(10):1495-504. doi: 10.1080/14760584.2022.2108798

La E, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among older adults in the United States. Poster presented at the 12th International RSV Symposium; September 29, 2022. Belfast, Ireland.

Weibel D, Sturkenboom M, Eijkemans R, van den Bor R, Elbers R, Plana E, Garcia de Albeniz X, Weinrib R, Yefimenko N, Bianchini E, Stona L, Poblador-Plou B, Swart-Polinder K, Bartolini C, Hyeraci RG, Roy D, Lupattelli A, Villalobos F, Barbieri E, Garg RK, Rubino H, De Luise C, Arana A. VAC4EU active safety surveillance study of the BNT162b2 COVID-19 vaccine in five European countries: study design and first results. Poster presented at the 2022 ICPE Conference; August 30, 2022. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2022 Sep 23; 31(S2):627-8. doi: 10.1002/pds.5518

Talbird SE, Carrico J, La EM, Carias C, Marshall GS, Roberts CS, Chen YT, Nyaku MK. Impact of routine childhood immunization in reducing vaccine-preventable diseases in the US. Pediatrics. 2022 Sep 1;150(3):e20210560. doi: 10.1542/peds.2021-056013

Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Mellott CE, Marshall GS, Roberts C. Value of the immunization program for children in the 2017 US birth cohort. Pediatrics. 2022 Sep 1;150(3):e20210560. doi: 10.1542/peds.2021-056007

Seeger JD, Jonsson Funk M, Bradley Layton J, Lloyd P. Considerations of misclassification and confounding on COVID-19 vaccines effectiveness studies - a Vaccine SIG endorsed symposium. Presented at the 2022 ICPE Conference; August 26, 2022. Copenhagen, Denmark.

Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Estimating the historical population-level impact of PCV13 national immunization programs on invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.

Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Non-vaccine serotype population-level trends for invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.

Anderson S, Talbird SE, Nossov M, Beattie N, Diaz-Mitoma F. Cost-effectiveness of 3-antigen vs. single-antigen vaccine for prevention of hepatitis B in adults in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Yi Z, Graham J, Diaz-Decaro J, Myers E, Buck P. The public health impact of routine vaccination in 16-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Sundaram V, Wasserman M, Palmborg A, McDade C, Dorange AC, Wilson M, Perdrizet J. Comparing the public health impact of the pediatric 15- and 20-valent pneumococcal conjugate vaccine in Sweden. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.

Sundaram V, Perdrizet J, Wasserman M, Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A. Comparing the public health impact of switching to pediatric 13-valent pneumococcal conjugate vaccine in the near-term and higher-valent pneumococcal conjugate vaccines in the long-term in the Netherlands. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.

Mikudina B, Vyse AJ, Czudek C, Ellsbury GF, Perdrizet J, Wasserman M, McDade C, Wilson M. Infant pneumococcal conjugate vaccine programs result in substantial cost-savings and cases averted in the United Kingdom. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.

Teixeira R, da Silva Maia AS, Sundaram V, Wasserman M, Horn EK, McDade C, Wilson M, Perdizet J. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine paediatric national immunisation programme in Portugal. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.

Flem E, Graham J, Yi Z, Wisloff T, Johnson KD. Cost and health impact analysis of herpes zoster vaccination in Norway. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):315-26. doi: 10.1080/14737167.2021.1973893

Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Herrera-Restrepo O, Buck PO. Health care providers' knowledge, practices, and barriers to hepatitis vaccination guidelines. J Nurse Pract. 2022 Feb 16;18:403-10.

Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022 Jan 24;40(3):483-93. doi: 10.1016/j.vaccine.2021.12.002

Carrico J, Mellott C, Talbird S, Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK. Economic evaluation of the pediatric immunization program in Belgium. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.

Herrera-Restrepo O, Ghaswalla P, Davis K, Sweeney C, Davenport E, Andani A, Buck PO. What can Europe learn from HCP knowledge and attitudes towards hepatitis A vaccination in the US? Poster presented at the 14th European Public Health Virtual Conference 2021 (EPH); November 10, 2021.

La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. National and state-level composite completion of recommended vaccines among adolescents in the United States, 2015-2018. J Adolesc Health. 2021 Nov;69(5):762-8. doi: 10.1016/j.jadohealth.2021.07.020

Curran D, Patterson B, Carrico J, Salem A, La E, Lorenc S, Hicks K, Poston S, Carpenter C. Cost-effectiveness analysis of recombinant Zoster vaccine for the prevention of herpes Zoster in immunocompromised adults diagnosed with select cancers in the United States. Poster presented at the 2021 Lymphoma and Myeloma (L&M) Virtual Congress; October 2021. [abstract] Am J Hematol. 2021 Oct 15; 96(S1):S26. doi: 10.1002/ajh.26351

Curran D, Patterson BJ, Carrico J, Salem AE, La EM, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the IDWeek 2021 Virtual Conference; September 29, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Bracher M, Birch H. Common symptoms in hospitalized COVID-19 patients by age, severity and survival outcome – A literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Birch H, Bracher M. The use of pharmacological therapies in hospitalized COVID-19 patients – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Lu E, Han E, Heyes AE, Mauskopf J, Bracher MG, Birch HJ. Economic burden associated with clinical management of COVID-19 – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x

Talbird S, Carrico J. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Presented at the 2021 National Adult and Influenza Immunization Summit Virutal Meeting; August 26, 2021.

Carrico J, Talbird SE, La EM, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Vaccine. 2021 Aug 23;39(36):5187-97. doi: 10.1016/j.vaccine.2021.07.029